Aaron Diantonio

Aaron is a scientific founder of Disarm Therapeutics. Aaron is investigating the development and maintenance of neural circuits at the Washington University School of Medicine in St. Louis. His laboratory defined the molecular mechanisms driving axon loss following injury and disease and identified novel therapeutic strategies to prevent or slow the progression of peripheral neuropathies and other neurological disorders. Together with Jeff Milbrandt he identified SARM1 as the central driver of axonal degeneration.

Aaron serves on the Scientific Advisory Board of the Children’s Discovery Institute and the Board of Directors of the Edward Mallinckrodt, Jr. Foundation. He organized the international meeting on the “Molecular Mechanisms of Axon Degeneration” at Jackson Laboratories in 2016 and served as Chair of the Synapses, Cytoskeleton, and Trafficking Study Section Study Section at the NIH. Aaron received research awards from the Keck, McKnight, Sloan, Mallinckrodt Foundations and the National Institutes of Health.

Aaron completed his undergraduate degree in biochemistry at Harvard University and a Master’s degree in biochemistry from Cambridge University in England. He earned his MD/PhD at Stanford University and carried out postdoctoral work at the University of California, Berkeley.